CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KLEIN, D. S.
Right arrow Articles by WILDS, P. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KLEIN, D. S.
Right arrow Articles by WILDS, P. R.

Canadian Journal of Anesthesia, Vol 30, 399-405, Copyright © 1983 by Canadian Anesthesiologists' Society

Review Article: Pulmonary Toxicity of Antineoplastic Agents: Anaesthetic and Postoperative Implications

DAVID S. KLEIN MD1 and PEGGY R. WILDS MS2

1 Department of Anesthesiology, Duke University Medical Center, Durham, NC
2 Division of Neurosurgery, University of North Carolina, Chapel Hill, NC

Address correspondence to: Dr. David S. Klein, Box 3094, Duke University Medical Center, Department of Anesthesiology, Durham, North Carolina 27710

Agents commonly used in the treatment of neoplastic diseases may impair pulmonary function, and a wide spectrum of agents are currently implicated as toxic to the pulmonary system. Agents most commonly implicated are bleomycin, carmustine, busulfan, methotrexate, and thoracic radiotherapy. Less commonly implicated agents include mitomycin, procarbazine, melphalan, chlorambucit, and cyclophosphamide. Therapeutic interactions at time of operation and postoperatively may exacerbate existing pulmonary damage. It is imperative for the physicians treating patients receiving antineoplastic therapy to recognize potentially dangerous therapeutic interactions, and adjust the therapeutic regimen acordingly. Concentrations of inspired oxygen must be maintained as low as is safely possible. Intruoperative monitoring of arterial and mixed venous oxygen tensions will enable the clinician to adjust inspired oxygen concentrations to the lowest possible level while maintaining adequate oxygen tensions to the tissues. A systematic review of antineoplastic agents currently implicated, drug-oxygen interactions, and a review of the pathophysiology are presented.

Key Words: PHARMACOLOGY CHEMOTHERAPEUTIC AGENTS: pulmonary toxicity, COMPLICATIONS: oxygen toxicity, pulmonary fibrosis.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the Canadian Anesthesiologists' Society.